Prevención de la carencia afectiva crónica: nuevos paradigmas en el modelo de familia de acogida temporal / Preventing chronic emotional deprivation: new paradigms in the foster family model

In Chile, most of infants whose biological family is not able to offer them a proper care are referred to a national child protection system and are early institutionalized. During their stay in the hospital and into childcare institution these infants lack of an exclusive and stable affect figure. This situation jeopardizes the child proper neurologic, affective and social development, commonly resulting in Chronic Emotional Deprivation. In this article the authors show a concise review of this concept and propose a novel foster family program, in an attempt to prevent and mitigate the occurrence of this disorder. The proposed program offers psychotherapeutic support and is based on the existence of a foster family having a one-time-only experience with exclusive dedication to just one child. This temporary family does not receive economic retribution and has the possibility to maintain contact with the child after his incorporation to a definitive family. The theoretical differences of the proposed program with the currently ongoing programs are explored and a clinical vignette is shown.

En Chile, la mayor parte de los recién nacidos que no cuentan con los cuidados de su familia de origen son derivados al sistema de protección y sometidos a una institucionalización temprana. Durante el periodo de internación -primero en el recinto asistencial y luego en una residencia para lactantes- el bebé carece de una figura de afecto exclusiva y estable. Esta situación compromete significativamente su desarrollo, siendo habitual en estos casos la presencia de un cuadro de Carencia Afectiva Crónica. Los autores brindan una breve revisión sobre este concepto e introducen un innovador programa de Familia de Acogida Temporal (FAT) que busca mitigar y prevenir el desarrollo de este cuadro. A diferencia de los programas actualmente en curso, se entrega un apoyo psicoterapéutico y se promueve que la familia de acogida temporal realice una única experiencia con dedicación exclusiva a un recién nacido, sin recibir remuneración económica por esta labor y con la posibilidad de mantener el vínculo con el infante después de su integración a una familia definitiva. Para dar cuenta del proceso psicoterapéutico, los autores entregan una viñeta clínica.

Tenosinovitis química de dedo medio por corticoides intraarticulares con evolución a síndrome compartimental en paciente con lupus eritematoso sistémico / Chemical tenosynovitis in middle finger after intra-articular corticosteroids infiltration evolving to compartment syndrome in a patient with systemic lupus erythematosus

Tenosynovitis is the inflammation of the tendon and synovial sheath. It is commonly affects hands and wrist. The etiology may be infectious or inflammatory. In patients with Systemic Lupus Erythematosus (SLE) the periarticular and tendinous commitment is frequent. Intra-articular corticosteroids (CO) are effective as adjuvant of the systemic therapy. Complications of use are infrequent. The case of a female patient is presented, 32 years old, with SLE and chronic renal failure secondary to lupus nephritis, chronic user of oral CO. She is infiltrates with intra-articular deposit betamethasone in metacarpal-phalangeal (MCP), because of articular edema. Twelve days later evolves with Compartment Syndrome (SC). Fasciotomy show findings compatible with chemical synovitis by betamethasone crystals. Currently there are quite few reports in the literature of CS with presentation in fingers. The diagnosis is mainly clinical. The common use of intra-articular CO is not without risk and should be planned and diagnosed early...

Tenosinovitis es la inflamación del tendón y vaina sinovial. Es más frecuente en manos y muñecas. Su etiología es infecciosa o inflamatoria. En pacientes con Lupus Eritematoso Sistémico (LES) el compromiso periarticular y tendíneo es frecuente. Los corticoides (CO) intraarticulares son efectivos como adyuvante de terapia sistémica. Las complicaciones de su uso son infrecuentes. Se presenta el caso de paciente sexo femenino, 32 años, con LES e insuficiencia renal crónica secundaria a nefropatía lúpica, usuaria de CO orales. Por edema articular se le infiltra betametasona de depósito intraarticular en metacarpo-falángica (MCF). Evoluciona doce días después con Síndrome Compartimental (SC). Durante la fasciotomía se evidencian hallazgos compatibles con sinovitis química por cristales de betametasona. Existe escaso reporte en la literatura de SC en dedos de la mano. El diagnóstico es principalmente clínico. El uso común de CO intraarticulares no está exento de riesgos y deben ser previstos y diagnosticados precozmente...

Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome.

BACKGROUND: Growing evidence points to irritable bowel syndrome physiologically as a disease of the enteric nervous system characterised by hypermotility. The aim of this study was to investigate the action of pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract on basal and post-prandial recto-anal motility of 40 irritable bowel syndrome patients in a random, double blind and placebo controlled trial. METHODS: Pinaverium bromide (50 mg) or placebo was taken orally t.i.d. with food. Myoelectrical and mechanical activities of the rectum and the internal anal sphincter were recorded before treatment for 2 h in the fasting state and for an additional 2 h post-prandial. RESULTS: Post-prandial rectal spike amplitude and frequency as well as the spontaneous recto-anal inhibitory reflex frequency decreased after pinaverium bromide (P < 0.01) but not after placebo. CONCLUSIONS: These results suggest that the calcium channel blockers acting selectively on the gastrointestinal tract may have a therapeutic role in patients with irritable bowel syndrome.

Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome

Background: Growing evidence points to irritable bowel syndrome physiologically as a disease of the enteric nervous system characterised by hypermotility. The aim of this study was to investigate the action of pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract on basal and post-prandial recto-anal motility of 40 irritable bowel syndrome patients in a random, double blind and placebo controlled trial. Methods: Pinaverium bromide (50 mg) or placebo was taken orally t.i.d with food. Myoelectrical and mechanical activities of the rectum and the internal anal sphincter were recorded before treatment for 2 h in the fasting state and for an additional 2 h post-prandial. Results: Post-prandial rectal spike amplitude and frequency as well as the spontaneous recto-anal inhibitory reflex frequency decreased after pinaverium bromide (P < 0.01) but not after placebo. Conclusions: These results suggest that the calcium channel blockers acting selectively on the gastrointestinal tract may have a therapeutic role in patients with irritable bowel syndrome.

Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome

Background: Growing evidence points to irritable bowel syndrome physiologically as a disease of the enteric nervous system characterised by hypermotility. The aim of this study was to investigate the action of pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract on basal and post-prandial recto-anal motility of 40 irritable bowel syndrome patients in a random, double blind and placebo controlled trial. Methods: Pinaverium bromide (50 mg) or placebo was taken orally t.i.d with food. Myoelectrical and mechanical activities of the rectum and the internal anal sphincter were recorded before treatment for 2 h in the fasting state and for an additional 2 h post-prandial. Results: Post-prandial rectal spike amplitude and frequency as well as the spontaneous recto-anal inhibitory reflex frequency decreased after pinaverium bromide (P < 0.01) but not after placebo. Conclusions: These results suggest that the calcium channel blockers acting selectively on the gastrointestinal tract may have a therapeutic role in patients with irritable bowel syndrome. (AU)

[Nitrite and nitrate content of meat and sausage products in the Republic of Cuba]. / Zum Nitrit- und Nitratgehalt von Fleisch- und Wurstwaren in der Republik Kuba.

283 samples of meat and sausages made from pork from the Meat-Works Colombia in the Country of Las Tunas--Republic of Cuba--have been analysed on their contents of nitrite and nitrate. On an average the investigated quantities lie much below the present tolerance limit in Cuba (125 mg/kg nitrite and 500 mg/kg nitrate). The authors recommend to lower the tolerance limit for nitrate in meat and sausages to 300 mg/kg.

Famotidina versus cimetidina en el tratamiento de la úlcera duodenal no complicada: estudio multicéntrico / Famotidine versus cimetidine in the treatment of uncomplicated duodenal ulcer: a multicenter study

La famotidina es un nuevo antagonista de receptores H2, con gran selectividad y afinidad para el sitio de enlace. Hipotéticamente, tiene mayor potencia y duración de efecto. Se llevó a cabo este estudio aleatorio y abierto, multicéntrico con el fin de evaluar la eficacia y seguridad de 40 mg de famotidina contra 800 mg de cimetidina, administrados como dosis única nocturna, en pacientes con úlcera duodenal no complicada. La respuesta al tratamiento se valoró endoscópicamente a las cuatro o seis semanas; se realizaron estudios clínicos y bioquímicos para evaluar la seguridad de la droga. Se estudiaron 90 sujetos, 47 recibieron famotidina y 43 cimetidina. A las cuatro semanas, las tasas de cicatrización fueron de 81% en el grupo con famotidina y 67% en el de cimetidina (P = 0.11). A las seis semanas los porcientes de cicatrización fueron de 98% y 88% respectivamente (P = 0.08). En los sujetos que no recibieron medicación anti-ulcerosa previa y/o en aquellos que tenían lesiones de > 1 cm, las tasas de cicatrización a las 4 semanas de tratamiento con famotidina fueron significativamente mayores (P < 0.05) a las obtenidas con cimetidina. El dolor diurno mejoró a la primera semana en el 93% y 83% de los pacientes que recibieron famotidina y cimetidina, respectivamente (P = 0.11); en cuanto al dolor nocturno, las tasas de mejoría fueron de 88% y 91% al cabo del mismo tiempo (P = 0.43). Se observaron efectos colaterales (atribuibles posiblemente a los fármacos) en seis pacientes (dos con famotidina y cuatro con cimetidina), todos ellos leves y reversibles una vez suspendido el trtatamiento. Los resultados sugieron que 40 mg de famotidina tienen utilidad y seguridad similares a 800 mg de cimetidina